Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02453087 · ClinicalTrials.gov registry record · Phase 1
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 7
- Study locations
NCT02453087: Completed Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche.
NCT02453087 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 66 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02453087, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 7
- Study locations
Study Summary
This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in combination with rituximab or obinutuzumab will be assessed.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Rituximab
- DRUG DCDS0780A
Study Locations (7)
California
- City of Hope National Medical Center - Duarte
- Stanford Cancer Center - Stanford
Colorado
- Medical Center of Aurora; Rocky Mountain Cancer Centers - Aurora
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Florida
- Florida Cancer Specialists - Sarasota (North Catttlemen Rd) - Sarasota
New York
- New York University Cancer Cen - New York
Oregon
- Willamette Valley Cancer Ctr - 520 Country Club - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-08-04 |
| Est. Completion | 2019-07-12 |
| Phase | Phase 1 |
What the finished NCT02453087 record still lists
NCT02453087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT02453087 lists 7 locations in 6 states (California, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02453087 about?
NCT02453087 is a clinical study titled "A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma". This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in...
What is the current status of trial NCT02453087?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-08-04. Estimated completion is 2019-07-12.
What conditions does trial NCT02453087 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02453087?
The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG), DCDS0780A (DRUG).
Who is sponsoring clinical trial NCT02453087?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02453087 being conducted?
This trial has 7 study locations across California, Colorado, District of Columbia, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02453087's enrollment target sits among peer trials
66 26th of 63 higher than 38 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI